Product Image

Contributor Information

  • Name Andrew Hollenbach
  • Institute Louisiana University Health Sciences Center New Orleans (LSU)

Tool Details

  • Tool name: Anti-phospho Pax3 [Ser209]
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Human ; Mouse
  • Host: Rat
  • Application: WB
  • Description: Pax3 is a transcription factor important for myogenesis and when dysregulated can cause pediatric solid muscle tumor alveolar rhabdomyosarcoma (ARMS). ARMS is primarily characterized by the t(2;13)(p35;p14) chromosomal translocation, which results in the oncogenic fusion protein Pax3-FOXO1. Using these phospho-specific antibodies it was demonstrated that the pattern of Pax3 phosphorylation at serines 201, 205, and 209 changes throughout early myogenic differentiation and that this pattern is different for Pax3-FOXO1 in primary myoblasts and in several ARMS cell lines.
  • Immunogen: synthetic peptide: NH2-DID(pS)EPDLPLKRC-CO2
  • Research area: Myogenesis

  • For Research Use Only

Target Details

  • Target: Phosphorylated Ser209 of Pax3
  • Target background: Pax3 is a transcription factor important for myogenesis and when dysregulated can cause pediatric solid muscle tumor alveolar rhabdomyosarcoma (ARMS). ARMS is primarily characterized by the t(2;13)(p35;p14) chromosomal translocation, which results in the oncogenic fusion protein Pax3-FOXO1. Using these phospho-specific antibodies it was demonstrated that the pattern of Pax3 phosphorylation at serines 201, 205, and 209 changes throughout early myogenic differentiation and that this pattern is different for Pax3-FOXO1 in primary myoblasts and in several ARMS cell lines.

Application Details

  • Application: WB

Handling

  • Format: Liquid
  • Shipping conditions: Shipping at 4°C

Documentation

  • Available on request

References

  •   Loupe et al. 2015. Oncogenesis. 4:e145. PMID: 25821947.
  •   Dietz et al. 2011. Int J Biochem Cell Biol. 43(6):936-45. PMID: 21440083.